Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Free Cash Flow (2023 - 2025)

Historic Free Cash Flow for Upstream Bio (UPB) over the last 3 years, with Q3 2025 value amounting to -$22.3 million.

  • Upstream Bio's Free Cash Flow fell 5974.79% to -$22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$122.5 million, marking a year-over-year decrease of 12005.57%. This contributed to the annual value of -$59.7 million for FY2024, which is 5677.17% down from last year.
  • Per Upstream Bio's latest filing, its Free Cash Flow stood at -$22.3 million for Q3 2025, which was down 5974.79% from -$39.2 million recorded in Q2 2025.
  • Upstream Bio's 5-year Free Cash Flow high stood at -$8.0 million for Q2 2024, and its period low was -$41.2 million during Q1 2025.
  • Moreover, its 3-year median value for Free Cash Flow was -$18.7 million (2024), whereas its average is -$22.3 million.
  • As far as peak fluctuations go, Upstream Bio's Free Cash Flow crashed by 2288.64% in 2024, and later crashed by 38829.02% in 2025.
  • Over the past 3 years, Upstream Bio's Free Cash Flow (Quarter) stood at -$16.1 million in 2023, then dropped by 22.89% to -$19.8 million in 2024, then fell by 12.66% to -$22.3 million in 2025.
  • Its Free Cash Flow stands at -$22.3 million for Q3 2025, versus -$39.2 million for Q2 2025 and -$41.2 million for Q1 2025.